CNQ · LYNX.CN
Lynx Resources Corp.
CA$0.14CA$0.00 (0.0%)
Lynx Resources Corp.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
Loading market information…
CNQ · TRYP.CN · CAD
Stock price, earnings
Quote as of Apr 29, 2024, 06:08 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tryp Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tryp Therapeutics Inc. is a pharmaceutical firm dedicated to discovering and advancing innovative compounds for medical conditions lacking adequate treatment options. Its primary research and development initiative, known as PFN, centers on utilizing synthetic psilocybin formulations to address a range of neuropsychiatric disorders. Key candidates within the PFN pipeline, TRP-8802 and TRP-8803, are being explored for potential applications in challenging conditions such as fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. To support its endeavors, Tryp Therapeutics has forged alliances, including an agreement with Calvert Labs for designing and conducting exploratory studies pertinent to its psilocybin-based neuropsychiatric program. Additionally, a service agreement with Fluence ensures specialized design and training for the psychotherapeutic components crucial to Tryp's clinical trial activities. Initially established as Artos Pharma Corp. in 2019, the company adopted its current name, Tryp Therapeutics Inc., in June 2020. It operates from its base in Kelowna, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.14CA$0.00 (0.0%)
Lynx Resources Corp.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
CA$0.08CA$0.00 (0.0%)
Mind Cure Health Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
CA$0.02CA$0.00 (0.0%)
SQI Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.67% below the high.
CA$0.04+CA$0.01 (+33.33%)
The BC Bud Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.19% below the high.
CA$0.12CA$0.00 (0.0%)
GeneTether Therapeutics Inc.: Healthcare · Biotechnology.
$5.93+$0.08 (+1.37%)
Clearmind Medicine Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.78% below the high.
CA$0.10-CA$0.04 (-25.93%)
Awakn Life Sciences Corp.: Healthcare · Biotechnology.
CA$0.10CA$0.00 (0.0%)
Asep Medical Holdings Inc’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
